Array BioPharma

This is a preliminary report on Array BioPharma’s security posture. If you want in-depth, always up-to-date reports on Array BioPharma and millions of other companies, consider booking a demo with us. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.

UpGuard Security Rating

/ 950
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Array BioPharma has good security practices.

Company info

Array BioPharma
Array BioPharma
Last updated
Last updated
Last updated today

Array BioPharma Data Breaches and Security News

Relevant news, breaches and security articles relating to Array BioPharma.
Last updated today

Security report for Array BioPharma

Array BioPharma is a U.S.-based, clinical stage, publicly traded pharmaceutical company founded in Boulder, Colorado (NASDAQ:ARRY) that is included in the NASDAQ Biotechnology Index.The company has engaged in collaborations with Pfizer and Merck to study several cancer targeting drug combinations. In July 2013 the company partnered with Loxo Oncology to develop cancer drugs, in November 2015 the company partnered with Pierre Fabre and the company also partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.In 2017 it spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.In March 2018 Array sued AstraZeneca for breach of contract, saying that AZ owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AZ in a deal for selumetinib, which Array said it had licensed to AZ in 2003.In June 2018, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) were approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.

More security reports

Compare Array BioPharma's security performance with other companies.
Deliver icon

Sign up to our newsletter

Get the latest curated cybersecurity news, breaches, events and updates in your inbox every week.
Abstract shapeAbstract shape
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan ratingAbstract shape

Book a free demo

Book a free, personalized onboarding call with one of our cybersecurity experts.
Want a deeper scan?
Get a guided tour of your organization’s security posture from an UpGuard team member.